Literature DB >> 22107865

Occlusive hyperemia versus normal perfusion pressure breakthrough after treatment of cranial arteriovenous malformations.

Brad E Zacharia1, Samuel Bruce, Geoffrey Appelboom, E Sander Connolly.   

Abstract

Arteriovenous malformations (AVMs) are vascular lesions characterized by direct connections between feeding arteries and draining veins without an intervening capillary network. Two hypotheses, normal perfusion pressure breakthrough (NPPB) and occlusive hyperemia, prevail in the literature regarding the occasional development of hemorrhage and edema following AVM resection. The NPPB hypothesis was introduced in 1978. Since the occlusive hyperemia hypothesis was first postulated in 1993, however, a debate has persisted within the cerebrovascular community concerning which hypothesis better explains the complications of edema and hemorrhage seen after AVM resection. Recent advances in cerebrovascular imaging and hemodynamic analysis have allowed a better evaluation of intracerebral changes following AVM resection. It is likely that these 2 hypotheses are not mutually exclusive and perhaps exist in a spectrum of hemodynamic alteration following AVM resection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22107865     DOI: 10.1016/j.nec.2011.09.005

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  2 in total

1.  Assessment of periprocedural hemodynamic changes in arteriovenous malformation vessels by endovascular dual-sensor guidewire.

Authors:  Kirill Orlov; Vyacheslav Panarin; Alexey Krivoshapkin; Dmitry Kislitsin; Vadim Berestov; Timur Shayakhmetov; Anton Gorbatykh
Journal:  Interv Neuroradiol       Date:  2015-02       Impact factor: 1.610

Review 2.  Normal perfusion pressure breakthrough theory: a reappraisal after 35 years.

Authors:  Leonardo Rangel-Castilla; Robert F Spetzler; Peter Nakaji
Journal:  Neurosurg Rev       Date:  2014-12-09       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.